| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.23▲ | 9.18▲ | 9.21▲ | 9.11▲ | 8.71▲ |
| MA10 | 9.23▲ | 9.18▲ | 9.13▲ | 8.90▲ | 12.53▼ |
| MA20 | 9.19▲ | 9.11▲ | 8.94▲ | 8.82▲ | 20.55▼ |
| MA50 | 9.17▲ | 8.87▲ | 9.03▲ | 15.06▼ | 17.32▼ |
| MA100 | 9.12▲ | 9.00▲ | 9.01▲ | 21.34▼ | N/A |
| MA200 | 8.96▲ | 9.02▲ | 8.50▲ | 19.02▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.008▲ | 0.008▲ | 0.051▲ | 0.553▲ | -2.036▼ |
| RSI | 63.581▲ | 61.315▲ | 62.513▲ | 42.454▼ | 34.180▼ |
| STOCH | 58.480 | 55.825 | 75.994 | 48.724 | 4.762▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -48.069 | -92.206▼ |
| CCI | 137.794▲ | 100.672▲ | 104.036▲ | 35.596 | -60.946 |
|
Thursday, March 26, 2026 04:00 AM
Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company ...
|
|
Tuesday, February 10, 2026 03:59 PM
Upstream Bio Inc.’s favorable top-line results from the phase II Valiant trial testing verekitug in adults with severe asthma were not enough to charm Wall Street, and shares of the firm (NASDAQ:UPB) ...
|
|
Tuesday, February 10, 2026 03:00 PM
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (UPB) (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/04/26 | 9.22 | 9.35 | 8.96 | 9.31 | 823,208 |
| 31/03/26 | 9.01 | 9.17 | 8.8223 | 9.00 | 1,009,167 |
| 30/03/26 | 8.53 | 8.78 | 8.29 | 8.78 | 862,814 |
| 27/03/26 | 8.74 | 9.14 | 8.10 | 8.67 | 938,057 |
| 26/03/26 | 9.6199 | 10.43 | 9.38 | 9.79 | 856,445 |
| 25/03/26 | 8.68 | 9.57 | 8.67 | 9.47 | 654,177 |
| 24/03/26 | 8.35 | 8.62 | 8.12 | 8.45 | 699,714 |
| 23/03/26 | 8.71 | 9.0298 | 8.43 | 8.45 | 728,848 |
| 20/03/26 | 8.38 | 8.68 | 8.1633 | 8.67 | 2,337,770 |
| 19/03/26 | 8.44 | 8.63 | 8.2303 | 8.38 | 733,628 |
|
|
||||
|
|
||||
|
|